Therapy News and Research

RSS

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA.

10 Dec 2012

Childhood obesity: an interview with Professor Clodagh O’Gorman

Childhood obesity is harder to define than adult obesity. This is because any definition of obesity relies on measurements of both height and weight, and the calculation of body mass index (BMI) based on these measurements.

10 Dec 2012

ATLAS holds up 10-year tamoxifen regime

Results from the ATLAS study indicate that women with estrogen receptor-positive breast cancer should consider taking tamoxifen for up to 10 years after diagnosis.

10 Dec 2012

Heart-healthy diet may reduce recurrent stroke, MI risk

Eating a “heart-healthy” diet may lower the risk for recurrent cardiovascular disease events in middle-aged individuals with a history of such conditions, researchers report.

10 Dec 2012

Rehabilitation helps restore erectile function post radical prostatectomy

Results from a study published in BJU International indicate that penile rehabilitation programs can help restore erectile function following nerve-sparing robot-assisted radical prostatectomy.

10 Dec 2012

RET fusion signals unique NSCLC subtype

The presence of RET fusion genes in approximately 1.5% of non-small-cell lung cancer defines a subset of tumors with distinct clinicopathologic features, research suggests.

10 Dec 2012

New assay test shows positive results for patients with recurrent or metastatic breast cancer

When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.

10 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

Surgical patients with chronic psychological symptoms require psychotherapeutic treatment

In their study, the research group, headed by Privatdozent Dr. Henning Krampe, psychologist at the Charité Department of Anesthesiology and Intensive Care Medicine, Prof. Claudia Spies, Director of the Charité Department of Anesthesiology and Intensive Care Medicine and Prof. Elmar Brähler, Head of the Department of Medical Psychology and Medical Sociology at the University of Leipzig, initially recorded how many patients faced by a forthcoming operation were interested in psychotherapy sessions and to what extent this interest was associated with the increased psychological distress occurring before the operation. Finally, the scientists examined whether changes in the psychological symptoms took place during the six months following the surgery.

10 Dec 2012

Physician's Technology launches WilloMD iLaserX device

The Italian Renaissance sculptor Michelangelo once declared "everything hurts". Baby boomers are more active than ever and stress their joints. Millions rely on dangerous pain meds and injections to stay active. Pain medication and injections can be dangerous and even lethal. Popular therapeutic pain laser technology offers hope but is not practical for home use and is out of reach of a vast patient population.

10 Dec 2012

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012